February 13, 2019
FDA warns of link between breast implants and anaplastic large cell lymphoma
Editor's Note
The Food and Drug Administration (FDA) on February 6 posted a letter that was sent to healthcare providers to increase their awareness of the association between all breast implants, regardless of filling or texture, and breast implant associated-anaplastic large cell lymphoma (BIA-ALCL).
As of September 30, 2018, the FDA has received 660 medical device reports of patients who have developed BIA-ALCL, generally within the scar capsule adjacent to the implant.
Free Daily News
- AMA urges stronger radiation protections
- Study: Digital tool detects preoperative pediatric anxiety, depression
- Hospital safety grades show progress in reducing medical errors, infections
- Analysis: Overuse of back surgeries costs Medicare $2 billion, risks patient safety
- AI-powered surgical robot learns by watching
- AHA's Congressional "wish list" calls for financial relief, patient access, workforce protections
- Out-of-hospital cardiac arrest survival rates lag pre-pandemic levels, racial disparities persist
- Honoring the OR Manager Award winners this Perioperative Nurses Week
- Study: Demand for anesthesiologists rises sharply, driven by job market, regional variations
- Joint Commission Sentinel Event Alert details environmental disaster preparation
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement